North America Hyperpigmentation Disorder Treatment Market

The North America hyperpigmentation disorder treatment market was valued at US$ 1,694.83 million in 2022 and is expected to reach US$ 3,028.73 million by 2030; it is estimated to register a CAGR of 7.5% from 2022 to 2030.

Rise in Prevalence of Melasma Fuels North America Hyperpigmentation Disorder Treatment Market

Melasma, one of the most dominant hyperpigmentation conditions, is characterized by symmetrical light to dark muddy-brown macules with borders on the face, particularly the chin, upper lip, nose, forehead, and cheeks. It is prevalent among women and those with darker complexion. Malar, mandibular, and centrofacial clinical features are common in melasma. Sun exposure, hormonal variations, pregnancy, hereditary factors, cosmetics, and medicines have all been linked to the development of melasma. Various studies have estimated that the overall prevalence of melasma in the general population ranges from 1% to 50%. 55–64% of melasma cases have reported a family history of the same condition. Moreover, a greater prevalence is reported in individuals of East Asian and Hispanic origins as well as in patients with high Fitzpatrick skin phototypes (IV to VI); it is also higher in individuals living in locations that receive intense UV radiation.

Pregnancy is another common cause of melasma. This condition also impacts women taking oral contraceptives and hormones. Estrogen, progesterone, and melanocyte-stimulating hormone levels normally rise during the third trimester of pregnancy, which may be a factor. According to the National Center for Biotechnology Information (NCBI) in August 2023, melasma is more common in reproductive years, and it rarely occurs before puberty; the condition occurs in 15–50% of pregnant women, and its prevalence ranges from 1.5% to 33%, depending on the population in a different region. Therefore, an upsurge in melasma prevalence triggers the demand for hyperpigmentation treatments.

North America Hyperpigmentation Disorder Treatment Market Overview

The hyperpigmentation disorder treatment market in North America is segmented into the US, Canada, and Mexico. The US held the largest North America hyperpigmentation disorder treatment market share in 2023. According to the Skin of Color Update 2024 (a dermatology conference), the demographics of the US are evolving with the growth of ethnic and racial diversity driven by international migration of Hispanics, Asian populations, and Africans in the country, which is also likely to lead to a minority-majority shift around the year 2050 toward individuals of Fitzpatrick III, IV, V, and VI skin types. Specifically, the Hispanic population is expected to be among the fastest-growing demographic groups in the US, with estimated growth from 55 million in 2014 to 119 million in 2060. A dark skin type is more prone to hyperpigmentation disorders.

The number of aesthetic procedures in the US has increased significantly over the last 10 years. According to the International Society of Plastic Surgeons (ISAPS), the number of nonsurgical aesthetic procedures rose by 19.9% in 2021 compared to 2020 globally. Intense pulsed light (IPL) treatment is among the top 5 minimally invasive cosmetic procedures, and ~827,000 IPL procedures were performed in the US in 2020. Thus, technological advancements in noninvasive procedures are likely to further benefit the hyperpigmentation disorder treatment market in the US. In March 2023, the US Food and Drug Administration (FDA) cleared Candela Corporation’s PicoWay laser to treat café au lait, melasma, lentigines, and Nevus of Ota. Previously, the laser system was approved for the treatment of benign pigmented lesions, acne scarring, wrinkles, and tattoo removal, among other indications.

Therefore, factors such as the growing ethnic and racial diversity, and the development of noninvasive medical aesthetic procedures such as cosmeceutics, chemical peels, cryotherapy, light, or laser therapy contribute to the hyperpigmentation disorder treatment market growth in the US.

North America Hyperpigmentation Disorder Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Hyperpigmentation Disorder Treatment Strategic Insights

Strategic insights for the North America Hyperpigmentation Disorder Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Hyperpigmentation Disorder Treatment Report Scope

North America Hyperpigmentation Disorder Treatment Regional Insights

The geographic scope of the North America Hyperpigmentation Disorder Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

North America Hyperpigmentation Disorder Treatment Market Segmentation

The North America hyperpigmentation disorder treatment market is categorized into treatment type, condition, end user, and country.

Based on treatment type, the North America hyperpigmentation disorder treatment market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held the largest market share in 2022.

Based on condition, the North America hyperpigmentation disorder treatment market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held the largest market share in 2022.

Based on end user, the North America hyperpigmentation disorder treatment market is segmented into hospitals, dermatology centers, and others. The hospitals segment held the largest market share in 2022.

By country, the North America hyperpigmentation disorder treatment market is segmented into the US, Canada, and Mexico. The US dominated the North America hyperpigmentation disorder treatment market share in 2022.

AbbVie Inc, Bayer AG, Galderma SA, L’OREAL S.A., Lutronic Co Ltd, Obagi Cosmeceuticals LLC, and Vivier Pharma Inc are some of the leading companies operating in the North America hyperpigmentation disorder treatment market.